Home > Rheumatology > ACR 2020 > Spotlight on Rheumatoid Arthritis > Persuasive long-term results for JAK inhibition in rheumatoid arthritis

Persuasive long-term results for JAK inhibition in rheumatoid arthritis

Presented By
Prof. Josef Smolen, Medical University of Vienna, Austria
Conference
ACR 2020
Trial
Phase 3, SELECT-MONOTHERAPY
Over 7 years, the oral JAK inhibitor upadacitinib showed convincing results for lasting efficacy in patients with rheumatoid arthritis within the SELECT-MONOTHERAPY trial. Upadacitinib as monotherapy already demonstrated significant results after 14 weeks in patients with moderate-to-severe rheumatoid arthritis (RA) compared with methotrexate within the SELECT-MONOTHERAPY (NCT02706951) study [1]. The current analysis focused on drug performance over 84 weeks [2]. Within the long-term extension of SELECT-MONOTHERAPY, 598 patients continued their previous medication with upadacitinib 15 or 30 mg or were switched to one of the upadacitinib doses in case of preceding methotrexate therapy, as prespecified at baseline. “By week 84, approximately 80% of patients in either treatment group, blinded upadacitinib 15 or 30 mg, remained in the study,” said Prof. J...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on